Jon Eckard, MD, TYME Inc., explains Explosion of Development Over Last 5-10 Years | Focus on the Patients Not Just…
Eric Jonasch, MD, UT MD Anderson Cancer Center explains Whether TKI & I-O Combinations are superior | Subgroups That Should…
Paul Nghiem, MD, PhD, University of Washington, shares Patients Who Dont Respond to Checkpoint Therapy | Collaborating to Pick Apart…
Eric Jonasch, MD, UT MD Anderson Cancer Center explains Assign Genomic & Transcriptomic Features | To Treatment Subtypes to See…
Petros Grivas, MD, PhD, University of Washington talks about Academic & Community Oncologists Must Collaborate | Accrue Trials to Develop…
Hannah Linden, MD, University of Washington shares Publish New Abstract Data Next Year | Complete Accrual of Estrogen Receptor Imaging…
Eric Jonasch, MD, UT MD Anderson Cancer Center explains Understanding Tumor Microenvironment | Using Omics Platforms to Assign Treatment at…
Petros Grivas, MD, PhD, University of Washington talks about Dynamic Era of Changes for Urothelial Cancer | Data with FGFR…
Hannah Linden, MD, University of Washington shares The Point of Estrogen Receptor Imaging? | If Receptor Functions & Need Endocrine…
Eric Jonasch, MD, UT MD Anderson Cancer Center explains I-O Treatment vs. TKI Treatment | TKI is Still Standard of…
Petros Grivas, MD, PhD, University of Washington talks about Whether Genomic Alterations Have Significance | And-Or Predict Response to Individual…
Hannah Linden, MD, University of Washington shares ER Imaging Not Ready for Commercial Use | Working Hard With Tracer Manufacturers…
Eric Jonasch, MD, UT MD Anderson Cancer Center explains Axitinib Titration Post-I-O Therapy | Change Dose to Maximize Quality of…
Petros Grivas, MD, PhD, University of Washington talks about Circulating Tumor DNA as a Putative Biomarker | For Patients with…
Dr. Jim Brugarolas, Director of the UT Southwestern Kidney Cancer Program, sat down with expert urologist, Dr. Vitaly Margulis, and…
Hannah Linden, MD, University of Washington shares Estrogen Receptor Imaging | Lobular Tumors Detectable by FES PET
Eric Jonasch, MD, UT MD Anderson Cancer Center explains Axitinib Titration Post-I-O Therapy | Change Dose to Maximize Quality of…
Acute myeloid leukemia (AML) is a highly heterogenous disease, and the specific mutations that are present in the patient play…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Andrew Wei,…
Andrew Wei, MBBS, PhD, FRACP, FRCPA, from Monash University, Melbourne, Australia, discusses clinical trials investigating the effect of BH3 mimetic…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Marion Subklewe,…
Marion Subklewe, MD, from LMU Hospital Munich, Munich, Germany, discusses several clinical trials in acute myeloid leukemia (AML) that are…
Paul Nghiem, MD, PhD, University of Washington, shares Collaborative Community Working to Understand MCC | Do Not Need Mutational Burden…
Eric A. Klein, MD, Cleveland Clinic explains No Good Screening Tests for Several Cancers | Able to See Early Signals…
Saveri Bhattacharya, DO, Thomas Jefferson University, talks about Therapies for Metastatic Breast Cancer | Clinical Trial Development is Key to…
Paul Nghiem, MD, PhD, University of Washington, shares Cannot Predict Who Responds to Immunotherapies | Response is 60% or More…
Eric A. Klein, MD, Cleveland Clinic, explains Tumor Cells Shed DNA & RNA | Technology Is Powerful Enough to Find…
Saveri Bhattacharya, DO, Thomas Jefferson University, talks about Triple Negative Breast Cancer Immunotherapies | Pemborlizumab works in NeoAdjuvant Setting at…
Eric A. Klein, MD, Cleveland Clinic, Preliminary Look at 10% of 15,000 Participants | Not Ready to be Applied to…
Saveri Bhattacharya, DO, Thomas Jefferson University, talks about Vaccine Immunotherapy with Cytoxan & Interferon | Eventually add Ipilimumab or Pembrolizumab…
Paul Nghiem, MD, PhD, University of Washington, shares Immunotherapy better than Chemo-Therapy More Durable, Works Better in the Frontline at…
Eric A. Klein, MD, Cleveland Clinic, explains how Test Must Have High Specificity | False-Positive Rate Must be Extraordinarily Low…
Saveri Bhattacharya, DO, Thomas Jefferson University, talks about Metastatic Breast Cancer Does Well with Bria-IMT Side-Effect Profile Not as Severe…
Paul Nghiem, MD, PhD, University of Washington, shares Immunotherapy & Chemo-Therapy with MCC Response is 60% or More If therapy…
Eric A. Klein, MD, Cleveland Clinic, explains The Circulating Cell-free Genome Atlas Study | Hope to Develop Multi-Cancer Screening Test…
Saveri Bhattacharya, DO, Thomas Jefferson University, talks about Phase 1 & 2 Trial of Bria-IMT | Immunotherapy with Cytoxan &…
Paul Nghiem, MD, PhD, University of Washington, explains Avelumab, for Metastatic Merkel Cell Carcinoma | Observed Responses are Durable at…
Here, Jacob Kettle, PharmD, BCOP, of the University of Missouri Health Care, Columbia, MO, shares his perspective on the different…
Results from clinical trials determine the effectiveness, toxicity and, ultimately, the approval of novel therapies for cancer. Here, Gregory Pond,…
Urothelial carcinoma has been a challenge for oncologists to treat for many years, with a steady mortality rate and no…
Jacob Kettle, PharmD, BCOP, of the University of Missouri Health Care, Columbia, MO, discusses the different ways in which pharmacists…
From the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference held in Denver, CO, Jacob Kettle, PharmD, BCOP, of the University…
With the involvement of so many genetic and molecular alterations in cancer, it is nearly impossible to know what pathway…
The recent Phase II VinCap trial (NCT02057913) shows promising results for vinflunine as a chemotherapy for locally-advanced and metastatic carcinoma…
In this interview, Christopher Campen, PharmD, BCOP, from the GHS Cancer Institute, Greenville, SC, discusses combining immune checkpoint inhibitors for…
The unique side effects that accompany the use of immune checkpoint inhibitors for the treatment of cancer need to be…
Patient-reported outcomes (PROs) give a greater insight into the lives of patients and their perspectives on the treatment received. Here,…
The expression of programmed death-ligand 1 (PD-L1) can be used as a clinical biomarker to determine the efficacy of immune…
Immune checkpoint inhibitors are effective in the management of various cancers. However, there are a number of side effects that…
Jennifer K. Litton, MD, explains The Number of Agents Has Exploded Impactful Studies Happen with Federal Funding at Annual Meeting…
Liviu Niculescu, MD PhD, explains Reanalysis of Study in Hodgkin Lymphoma 23% Reduction in Risk of Modified PFS at Annual…
Jennifer K. Litton, MD, MD Anderson Cancer Center, talks about TAILORx Trial is Confirmatory Group of Patients Avoiding Chemo-Therapy at…
Liviu Niculescu, MD PhD, explains Frontline Trials to Show if Alunbrig is Superior Figure What is the Best Sequencing for…
Jennifer K. Litton, MD, MD Anderson Cancer Center, talks about Warranting Larger Ongoing Confirmatory Study Possibility of Avoiding Chemo-Therapy in…
Lisa A. Rometty, IBM Watson Health, shares Pioneering Work with VA Precision Oncology Disproportionate Amount of Patients in Rural Areas…
Liviu Niculescu, MD PhD, explains Patients Have Other Companies & Research Groups Working with Colleagues to Advance Life of Patients…
Jennifer K. Litton, MD, MD Anderson Cancer Center, shares Biopsies Pre- & Post-PARP inhibitors Combination Studies for Response Beyond BRCA…
Lisa A. Rometty, IBM Watson Health, shares how Watson is in Over 200 Hospitals Around the World Physician to Patient…
Liviu Niculescu, MD PhD, explains Newly Diagnosed Patients with ALK-Positive Disease Are Being Randomized with Alunbrig at Annual Meeting 2018
Jennifer K. Litton, MD, MD Anderson Cancer Center, shares Warrants Larger Ongoing Confirmatory Study Possibility of Avoiding Chemo-Therapy in BRCA…
Lisa A. Rometty, IBM Watson Health, shares AI Technology Matches Info to Clinical Trial Criteria Increased Number of Patients Matched…
Liviu Niculescu, MD PhD, explains How To Make Sense of the Amount of Information Focus on the Most Important Data…
Jennifer K. Litton, MD, MD Anderson Cancer Center, shares Feasibility Study with 2 Months of Talazoparib Tumor Volume Decrease of…
Lisa A. Rometty, IBM Watson Health, Watson Uses AI Technology with Analytic Data To Package All Information into One Place…
Liviu Niculescu, MD PhD, Alunbrig – Drug for ALK-Positive Lung Cancer 56% Overall Response Rate at Annual Meeting 2018
Jennifer K. Litton, MD, MD Anderson Cancer Center, shares Talazoparib – Active in Metastatic Breast Cancer Pathologic Complete Response Rate…
Lisa A. Rometty, IBM Watson Health, talks about Augmented Intelligence Plays Important Role Enabling Value in Precision Oncology at Annual…
Jon Eckard, PhD, TYME Inc., explains Not Much Getting Approval for Pancreatic Cancer | Cost of cancer care is very…
Michelle Dawson, MD, AstraZeneca, talks about Chemo-free Regimens for Patients Moxetumomab delivers different experience at Annual Meeting 2018.
Jon Eckard, PhD, TYME Inc., explains Taking Advantage of the Metabolism of a Cancer Delivering drug specifically to the cancer…
Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses the new and exciting clinical trials…
Christoph Röllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, discusses the rationale behind determining the most suitable…
Rafael G Amado, MD, Adaptimmune, LLC, explains Engineer T-Cell Receptors, Affinity Matured Can recognize and kill tumor cells at Annual…
Michelle Dawson, MD, AstraZeneca, talks AstraZeneca is Relatively New Six Agents in Phase 1 & another Six in Phase 2…
Jon Eckard, PhD, TYME Inc., explains Development in Solid & Liquid Tumor Front Complete & partial response in Hodgkins, Non-Hodgkins…
Rafael G Amado, MD, Adaptimmune, LLC, explains Updates of Positive CAR-T Studies & Approval Speaks to the power and potential…
Michelle Dawson, MD, AstraZeneca, talks about FDA Accepted Moxetumomab BLA Studies looking for toxicities and developments at Annual Meeting 2018.
Jon Eckard, PhD, TYME Inc., explains Patients Tired of Toxic Chemotherapies Current data shows efficacy & maintaining quality of life…
Rafael G Amado, MD, Adaptimmune, LLC, explains Expanding Cohorts of Patients to Verify Results Increase number of cells & intensity…
Michelle Dawson, MD, AstraZeneca, talks about Adverse Effects for Moxetumomab Pasudotox Mild percentages of headache, nausea, HUS, CLS at Annual…
Jon Eckard, PhD, TYME Inc., explains Studies Today are Focused on Biomarkers Not Biomarker specific, broad efficacy at Annual Meeting…
Rafael G Amado, MD, Adaptimmune, LLC, Hopes T-cell Therapies Will Lead to Approval Difficult to treat solid tumors with adoptive…
Michelle Dawson, MD, AstraZeneca, talks about Moxetumomab Pasudotox is Unique Immunotoxin Fused pseudomonas exotoxin with antibody variable at Annual Meeting…
Jon Eckard, PhD, TYME Inc., talks about Four Drug Combination – effects driven by one drug With other drugs supplementing…
Michelle Dawson, MD, AstraZeneca, talks about 75% Overall Response from Moxetumomab 41% of patients had complete response at Annual Meeting…
Rafael G Amado, MD, Adaptimmune, LLC, explains Between 1-5 Billion Cells Given to Patients Cytokine Release Syndrome resolved with antiIL-6…
Jon Eckard, PhD, TYME Inc., shares Trial Designed to Target Unique Tumor Biology Most cancer therapies come with side-effects at…
Michelle Dawson, MD, AstraZeneca, talks about Moxetumomab Pasudotox Pivotal in relapse refractory hairy cell leukemia at Annual Meeting 2018.
Rafael G Amado, MD, Adaptimmune, LLC, explains MRCLS Responded to Active Therapy Treatment Harvested T-Cells transduced with antiviral vector at…
Jon Eckard, PhD, TYME Inc., explains Ongoing Phase II Pancreatic Cancer Trial Metabolic therapy is tumor-treating, patient-sparing at Annual Meeting…
Michelle Dawson, MD, AstraZeneca, talks about Acalabrutinib (Calquence) Approved For relapsed or refractory mantle cell lymphoma at Annual Meeting 2018.
Rafael G Amado, MD, Adaptimmune, LLC, explains Infusion of T-Lymphocytes with T-Cell Receptor MRCLS could be sensitive to therapy at…
Martina A. Sersch, MD, Executive Medical Director at Amgen Inc., talks about Many Drugs Being Looked at for Multiple Myeloma…
Seth M. Pollack, MD, Fred Hutchinson Cancer Research Center, shares Myxoid Round Cell Liposarcoma Expresses NY-ESO-1 T-Cell therapy targeting NY-ESO-1…
Ahmad Tarhini, MD, PhD, Cleveland Clinic Main Campus, talks about Adjuvant Data Changing Clinical Practice Moving into Anti-PD-1 monotherapy, and…
Martina A. Sersch, MD, Executive Medical Director at Amgen Inc., shares Trials of BCMA BiTE Platform & CAR-T Cell Early…
Seth M. Pollack, MD, Fred Hutchinson Cancer Research Center, talks about Creating a number of followup studies Testing checkpoint Inhibitors,…
Ahmad Tarhini, MD, PhD, Cleveland Clinic Main Campus, shares Economics Outcome Research More Important Guiding clinicians & policy makers, survival…
Seth M. Pollack, MD, Fred Hutchinson Cancer Research Center, explains Lots of Patients with Refractory Sarcomas Considering Off-Label Checkpoint Inhibitor
Ahmad Tarhini, MD, PhD, Cleveland Clinic Main Campus, talks about Data is Hypothesis-Generating Data is still useful for determining optimal…
Martina A. Sersch, MD, Executive Medical Director at Amgen Inc., shares Safety Profile of Once-Weekly Regimen Was comparable opposed to…
Seth M. Pollack, MD, Fred Hutchinson Cancer Research Center, explains Undifferentiated Pleomorphic Sarcoma Can respond to checkpoint blockade like pembrolizumab…
Ahmad Tarhini, MD, PhD, Cleveland Clinic Main Campus, talks about ECOG-ACRIN EA6134 Ipilimumab + Nivolumab vs. Dabrafenib + Trametinib at…
Martina A. Sersch, MD, Executive Medical Director at Amgen Inc., shares Novel Endpoints in MRD in Multiple Myeloma Novel Drugs…
Seth M. Pollack, MD, Fred Hutchinson Cancer Research Center, explains Sarcoma Subtypes React to Different Immunotherapy Have inflammatory tumor-immune micro-environments…
Ahmad Tarhini, MD, PhD, Cleveland Clinic Main Campus, shares Economic Outcome Analysis for BRAF Melanoma Anti-CD4+PD-1, & Anti-PD-1 both followed…
Martina A. Sersch, MD, Executive Medical Director at Amgen Inc., discusses Data from ARROW Trial for Multiple Myeloma Progression-free survival…
Dr. Nasser Hanna, Indiana University Health, considers the use of induction or consolidation chemotherapy for unresectable stage III NSCLC.
Dr. Nasser Hanna, Indiana University Health, discusses the development of chemoradiation as a standard of care for unresectable stage III…
Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, discusses Gentlemen’s Study Originally for All Men in WA Now available…
Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, discusses Areas of Research in 2018-19 include Combination therapy, CARP Inhibitors,…
Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, explains Waldenstrom Macroglobulinemia is Rare Disease Results of study…
Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, discusses Combination Study of Olaparib & Abiraterone Especially for patients with…
Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, talks about Better Defining Nature of Mutations of Genes…
Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, explains Acalabrutinib is Another BTK Inhibitor Active drug for…
Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, discusses Further Characterize Identified Mutations A lot of work to be…
Chuck Wiseman, MD, BriaCell Therapeutics, talks about Rollover Protocol Approval Bria-IMT in combination with a checkpoint inhibitor at Annual Meeting…
Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, talks about Devising Future Trials That Add Another Agent…
Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, discusses Underserved & Underepresented Patient Population African-Americans have higher risk of…
Chuck Wiseman, MD, BriaCell Therapeutics, discusses Capitalizing on Matching HL-Antigens Key to developing clinically relevant immune response at Annual Meeting…
Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, explains BTK Inhibitors Associated with Atrial Fibrillation Only 4%…
Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, explains how Patients Can Learn More About Gentlemen’s Study from www.gentlemenstudy.org…
Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, explains Ibrutinib & Rituximab is a new standard for…
Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, discusses Gentlemen’s Study for Metastatic Prostate Cancer Trial offers testing in…
Chuck Wiseman, MD BriaCell Therapeutics, discusses Cell Preparation Bria-IMT Confirms that similar vaccine therapies can regress advances at Annual Meeting…
Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, explains Innovate Trial – Randomized Placebo Control 150 patients…
Dr. Nasser Hanna, Indiana University Health, reviews efforts to utilize targeted therapies as consolidation after chemoradiation in locally advanced NSCLC
Heather H. Cheng MD, PhD, Seattle Cancer Care Alliance, discusses New Treatments for Prostate Cancer Identified from Tumor & Germline…
Application of 2% Sequester Cut to Medicare Part B Drug Reimbursement is Unconstitutional and Illegal; Costing Seniors and Taxpayers Billions…
Jinghui Zhang, PhD, St. Jude Children’s Research Hospital, explains Genome Sequencing Enable a Complete Picture Additional analyses not found on…
Chinthalapally V. Rao, PhD, Stephenson Cancer Center, talks about Marginal Beneficial Effects After 6 Months to 1 Year Limitations of…
Jinghui Zhang, PhD, St. Jude Children’s Research Hospital, explains Researchers Upload Data With St. Jude Cloud Goal is to Enable…
Scott Newman, PhD, St. Jude Children’s Research Hospital, explains What is St. Jude Cloud? Bring tools to the data &…
Jinghui Zhang, PhD, St. Jude Children’s Research Hospital, explains Access, Analyze, & Visualize Genomic Data Offer 5,000 Genome sequencing datasets…
Chinthalapally V. Rao, PhD, Stephenson Cancer Center, talks about Aspirin Prevents Colorectal Cancer Progress Patients subconsciously taking aspirin may cause…
Paul A. Northcott, PhD, St. Jude Children’s Research Hospital, explains Examples of Genes Activated by Enhancer Hijacking Validate findings based…
Scott Newman, PhD, St. Jude Children’s Research Hospital, explains St. Jude Cloud Reanalyzed coding variants Some B-Cell ALL have mutational…
Jinghui Zhang, PhD, St. Jude Children’s Research Hospital, explains Cloud-Computing – Centralized Infrastructure Enables access of data for all research…
Paul A. Northcott, PhD, St. Jude Children’s Research Hospital, explains Linking Aberrations to Oncogene De-Regulation Unable to make 1-to-1 correlation…
Timothy Yap, MBBS, Ph.D., MD Anderson Cancer Center, talks about MD Anderson Provides Screenings for Therapies Reviewed by Precision Oncology…
Elaine R. Mardis, PhD, The Institute for Genomic Medicine, talks about Next Meeting will Showcase Modern Technology Next generation sequencing…
Paul A. Northcott, PhD, St. Jude Children’s Research Hospital, explains Novel Mechanisms of Oncogene De-Regulation Integrative Genomic Approaches to implicate…
Emily L. Harris, Ph.D., M.P.H.,National Cancer Institute – Deputy Associate Director, explains ARA Process for Large Budget Grants Program director…
Elaine R. Mardis, PhD, The Institute for Genomic Medicine, talks Cancer Care for Pediatctrics and Young Adults Rare diseases in…
Dr. Nasser Hanna, Indiana University Health, lists chemo regiments appropriate for use with radiation in locally advanced NSCLC.
Timothy Yap, MBBS, Ph.D., MD Anderson Cancer Center, talks about Understanding Intratumor Heterogeneity Founding ubiquitous mutations vs. heterogeneous events at…
Dr. Nasser Hanna, Indiana University Health, discusses the possible role of immunotherapy in locally advanced NSCLC.
Emily L. Harris, Ph.D., M.P.H., National Cancer Institute – Deputy Associate Director, explains Three Main Data Sharing Policies Large Budget…
Timothy Yap, MBBS, Ph.D., MD Anderson Cancer Center, talks about Abnormalities With Next-Gen Sequencing Widen therapeutic options by tailoring trials…
Elaine R. Mardis, PhD, The Institute for Genomic Medicine, explains 80% of Patients Don’t go to Tertiary Centers Making sure…
Emily L. Harris, Ph.D., M.P.H.,National Cancer Institute – Deputy Associate Director, explains NIH Data Sharing Accelerates Research Progress Sharing broadly…
Timothy Yap, MBBS, Ph.D., MD Anderson Cancer Center, explains TRK-Inhibitor, Larotrectinib Can administer to patients with TRK-fusions at AACR 2018.
Elaine R. Mardis, PhD, The Institute for Genomic Medicine, talks about Variety of Developments in Cancer Genomics Translate discoveries in…
Timothy Yap, MBBS, Ph.D., MD Anderson Cancer Center, FDA Approval of Pembrolizumab The 1st approval of a drug that is…
Despite major advancements in the understanding of the genetic drivers of acute myeloid leukemia (AML) and the pathophysiology of the…
Gail Roboz, MD, from the Weill Medical College of Cornell University, New York City, NY, explores exciting next-generation agents for…
Patients suffering from acute myeloid leukemia (AML) who have achieved complete remission are still at risk of relapse. Assessing blood…
The average age of people suffering from acute myeloid leukemia (AML) is around 60 to 70 years, and there are…
Noelle Frey, MD, from the University of Pennsylvania, Philadelphia, PA, highlights the importance of minimal residual disease (MRD) assessment in…
Unlike childhood acute lymphoblastic leukemia (ALL), there are currently no approved CAR T-cell products for the treatment of adult ALL;…
CAR T-cell therapy has proven effective in delivering high response rates in relapsed acute lymphoblastic leukemia (ALL) patients, but what…
Treatment outcomes for acute myeloid leukemia (AML) patients treated with immunotherapy have significantly lagged behind those achieved for acute lymphoblastic…
Despite recent approvals of drugs targeting acute myeloid leukemia (AML), overall survival and complete remission rates remain suboptimal. In this…
Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses the mechanisms of resistance to targeted…
The side effects of isocitrate dehydrogenase (IDH) inhibitors for the treatment of acute myeloid leukemia (AML) include gastrointestinal toxicity, leukocytosis,…
Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, explains the mechanisms of isocitrate dehydrogenase (IDH)…
Traditionally, the standard therapy for the management of acute myeloid leukemia (AML) in elderly patients has been low-dose cytarabine, but…
Minimal residual disease (MRD) is a highly important prognostic indicator used to determine treatment efficacy in acute myeloid leukemia (AML)…
Patients suffering from acute myeloid leukemia (AML) who have achieved complete remission are still at risk of relapse. Assessing blood…
Gemtuzumab ozogamicin is a monoclonal antibody drug for the treatment of acute myeloid leukemia (AML). This drug uses a different…
Christoph Röllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, discusses how his team is carrying out treatment…
Christoph Röllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, explains how the lack of novel drugs for…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Charles Mullighan,…
Minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) is now considered to be an equal, or greater, marker…
Charles Mullighan, MBBS (Hons), MSc, MD, from St. Jude Childrens Research Hospital, Memphis, TN, discusses the novel and interesting approaches…
Finding the right treatment for a specific subset of acute lymphoblastic leukemia (ALL) requires a correct diagnosis, but there are…
Charles Mullighan, MBBS (Hons), MSc, MD, from St. Jude Childrens Research Hospital, Memphis, TN, provides an overview of his talk…
Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany, discusses the importance of collaborating with other trial groups that…
Midostaurin is a tyrosine kinase inhibitor that has been newly approved for the treatment of acute myeloid leukemia (AML). In…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Arnold Ganser,…
Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany, discusses the research carried out by some of his former…
Dealing with patients with refractory acute myeloid leukemia (AML) or with those who have relapsed, is challenging, and stem cell…
Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany talks about his experience of the 2018 European School of…
Dr. Nasser Hanna, Indiana University Health, addresses the issue of prophylactic cranial irradiation (PCI) in locally advanced NSCLC.
Elaine R. Mardis, PhD, The Institute for Genomic Medicine, talks about Big Shoes to Fill as President of AACR Association…
Charis Eng, MD, PhD, Genomic Medicine Institute – Cleveland Clinic, explains KLLN & SEC23B Novel Predisposition Genes Prediction tools for…
Charis Eng, MD, PhD, Genomic Medicine Institute – Cleveland Clinic, explains SEC23B is Altered For Rare Blood Disorder Type II…
Charis Eng, MD, PhD, Genomic Medicine Institute – Cleveland Clinic, explains SEC23B is Very Rarely Studied in Cancer Enters the…
Charis Eng, MD, PhD, Genomic Medicine Institute – Cleveland Clinic, explains KLLN is Right Next to PTEN Gene Might play…
Charis Eng, MD, PhD, Genomic Medicine Institute – Cleveland Clinic, explains 3D Modeling of PTEN Tumor Suppressor at AACR 2018.
How Do Thoracic Surgeons Assess Fitness for Surgery
Dr. David Harpole, Duke University Medical Center, describes the mediastinoscopy and its use in lung cancer staging.
Dr. David Harpole, Duke University Medical Center, describes the sleeve resection and how it can help selected patients with large…
Dr. David Harpole, Duke University Medical Center, defines the concept of mediastinal node sterilization and its use after neoadjuvant therapy.
Dr. David Harpole, Duke University Medical Center, compares traditional open thoracotomy with video-assisted thorascopic surgery, highlighting the advantages of the…
Dr. Benjamin Levy, Mount Sinai Health Systems, lists the goals of treating advanced NSCLC and the methods used to achieve…
Dr. Jack West reviews his top 5 abstracts in stage I-III non-small cell lung cancer, small cell lung cancer, and…
How Rate of Progression Can Affect Treatment Decisions
Dr. Jack West reviews his top 5 abstracts in the advanced NSCLC track at ASCO 2018, explaining why each is…
Dr. Benjamin Levy, Mount Sinai Health Systems, compares zoledronic acid and denosumab, two agents used for treatment of bone metastases…
Dr. Heather Wakelee, Stanford University Medical Center, discusses the purpose of adjuvant chemotherapy, and which patients benefit most from it.
Dr. Heather Wakelee, Stanford University Medical Center, lists standard adjuvant chemotherapy regimens, comparing their administration and uses.
Dr. Heather Wakelee, Stanford University Medical Center, evaluates the lack of evidence for the use of targeted therapies after surgery,…
Dr. Ross Camidge, University of Colorado, discusses the potential benefits as well as the disadvantages of multiplex mutation testing.
Dr. Ross Camidge, University of Colorado, describes ALK rearrangements and the characteristics of patients who most often have them.
Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and…
Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment…
Scott Kopetz, M.D., Ph.D., FACP, discusses Safety Lead-In from the Beacon Study 48% Overall Response Rate
Scott Kopetz, M.D., Ph.D., FACP, explains Less Predictable Alternate BRAF Mutations Not all BRAF mutations are the same.
Scott Kopetz, M.D., Ph.D., FACP, discusses Getting Patients into Clinical Trial Sooner than Later Start with aggressive cytotoxic backbone
Scott Kopetz, M.D., Ph.D., FACP, explains the Rare Clones of KRAS Mutant Cells Able to identify resistant clones
Scott Kopetz, M.D., Ph.D., FACP, explains BRAF V600E Mutation BRAF with EGFR Provided Synergy.
Dr. Ross Camidge, University of Colorado, describes the second generation ALK-inhibitors which provide good options for ALK-positive NSCLC patients who…
Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between…
Community Oncology Alliance Statement on President’s Blueprint to Lower Drug Prices Putting Cancer Patients First and Lowering Drug is Critically…
Community Oncology Alliance Names Dr. Frederick M. Schnell to Newly Created Medical Director Position Experienced Community Oncologist Will Provide Valuable…
Community Oncology Alliance Statement on White House Budget Proposal Drug Price Recommendations Administration’s Budget has Numerous Smart, Overdue Policy Solutions;…
Journalist, author and television host Joan Lunden sat down with COA executive director Ted Okon to discuss her latest book…
Scott Hamilton discusses the importance of the health care industry and everyone on the cancer care team.
COA Cancer Policy Minute with Ted Okon This Cancer Policy Minute video is part of Community Oncology TV.
Pharmacy Benefit Managers (PBMs): Abusive Middlemen COA Cancer Policy Minute with Ted Okon
Did you know that the majority of Americans battling cancer receive their care in what is known as a community…
COA Patient Advocacy Network (CPAN) advocates talk about what being a part of CPAN means to them.
COA Cancer Policy Minute with Ted Okon. This Cancer Policy Minute is part of the Community Oncology TV series.
Community oncology practice New England Cancer Specialists (NECS) is always looking forward, providing high quality, data-driven, low cost cancer care.
Community oncology practices like Augusta Oncology take care of the whole patient, from diagnosis and treatment to social and financial…
NFL linebacker and Super Bowl champion Mark Herzlich of the New York Giants sat down with with COA executive director…
NFL linebacker and Super Bowl champion Mark Herzlich of the New York Giants discusses how he created a team of…
Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first…
Dr. Jack West, Swedish Cancer Institute, identifies the platinum-based chemotherapy doublet as the backbone of first-line treatment for the majority…
Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for…
Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology
Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology.
H. Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Founder & President, Grace Global Resource for Advancing…
H. Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Founder & President, Grace Global Resource for Advancing…
H. Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Founder & President, Grace Global Resource for Advancing…
H. Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Founder & President, Grace Global Resource for Advancing…
Thrombotic microangiopathy (TMA) is a rare complication that may arise post-transplant in patients, however, incidence of TMA has increased in…
The complications in blood and marrow transplantation can be serious with rapid onset, therefore ideal donor matching is crucial in…
Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Mohamad Mohty, MD,…
There has been an increase in the number of patients with refractory hematological malignancies being referred to transplant centers, although…
The therapeutic landscape of Hodgkin lymphoma has improved considerably over the past 50 years, with patient outcomes improving due to…
Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.
Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance…
Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.
Dr. Jed Gorden, Swedish Cancer Institute, describes the differences between bronchoscopy and endobronchial ultrasound, highlighting the advantages of EBUS in…
Dr. Jed Gorden, Swedish Cancer Institute, reviews the lung cancer screening process, including low-dose CT scanning, smoking cessation, follow-up testing…
Dr. Jack West, Swedish Cancer Institute, raises the question of whether to use immune checkpoint inhibitors as first-line treatment of…
Dr. Jack West, Swedish Cancer Institute, discusses current trials seeking to determine the efficacy of combining immunotherapy agents in lung…
1st Video in the GRACE ASCO 2016 Lung Cancer Roundtable series, featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD,…